A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 6, 1998, Pages 989-995

  Goslings, Willem R O ^a,b   Prodeus, Andrey P ^a   Streilein, J Wayne ^a   Carroll, Michael C ^a   Jager, Martine J ^b   Taylor, Andrew W ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASCORBIC ACID; COMPLEMENT COMPONENT C1Q; COMPLEMENT INHIBITOR;

ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; AQUEOUS HUMOR; ARTICLE; COMPLEMENT HEMOLYSIS TEST; FLOW CYTOMETRY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0031958578     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Law SKA, Reid KBM. In: Male D, ed. Complement. 2nd ed. Oxford, UK: IRL; 1996:1-88.
2. Lachmann PJ, Müller-Eberhard HJ. The demonstration in human serum of conglutinogen activity factor and its effect on the third component of complement. J Immunol. 1968;100:691-698.
3. Pensky J, Schwick HG. Human serum inhibitor of C1 esterase: identity with a 2 neuroaminoglycoprotein. Science. 1969;163:698-699.
4. Whaley K, Ruddy S. Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator (C3b INA). Science. 1976;193:1011-1013.
5. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994;15:369-396.
6. Lass JH, Walter EI, Burns TE, et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci. 1990;31:1136-1148.
7. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci. 1993;34:3579-3584.
8. Bora NS, Kabeer NH, Kim MC, Paryjas S, Atkinson JP, Kaplan HJ. Expression of the complement regulatory proteins in the normal and diseased (EAU) rat eye. In: Nussenblatt RB, Witcup SM, Caspi RR, Gery J, eds. Advances in Occular Immunology. Amsterdam: Elsevier: 1994:83-86.
9. Shimada K. The complement components and their inhibitors in the intraocular fluids of the guinea pig. Invest Ophthalmol. 1970; 9:304-315.
10. Mondino BJ, Sumner H. Complement inhibitors in normal cornea and aqueous humor. Invest Ophthalmol Vis Sci. 1984;25:483-486.
11. Liao HR, Minta JO, Basu PK. Anticomplementary activity of corneal vitreous and chorioretina in rabbits. Can J Ophthalmol. 1979;14: 270-273.
12. Zheng XB, Peng Q, Sha L. Anticomplement activity in human aqueous humor. Ophthalmic Res. 1994;26:200-202.
13. D'Ermo F, Lanziera M, Cricchi M, Ovary Z. Research into the complementary and anticomplementary power of aqueous humor and vitreous of guinea pigs. Boll Ocul. 1960;39:643-649.
14. Harbeck RJ, Giclas PC. Assessment of complement components and their function. In: Horbeck RJ, Griclas PC, eds. Diagnostic Immunology Laboratory Manual. New York: Raven Press; 1991: 1-116.
15. Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM, eds. Experimental Immunochemistry. Springfield, IL: Charles C Thomas; 1961:133-240.
16. Riley MV. The chemistry of the aqueous humor. In: Anderson RE, ed. Biochemistry of the Eye. San Francisco, CA: American Acadamy of Ophthalmology; 1983:79-95.
17. Berman ER. Aqueous, iris-ciliary body, and trabeculum. In: Biochemistry of the Eye. New York: Plenum Press; 1991:151-200.
18. Chang NS, Boackle RJ, Armand G. Hyaluronic acid-complement interactions I: reversible heat-induced anticomplementary activity. Mol Immunol. 1985;22:391-397.
19. Burton DR. Immunoglobin G: functional sites. Mol Immunol. 1985;22:161-206.
20. Fridkin M, Najjar VA. Tuftsin: its chemistry, biology, and clinical potential. Crit Rev Biochem Mol Biol. 1989;24:1-40.
21. Duncan AR, Winter G. The binding site for C1q on IgG. Nature. 1988;332:738-740.
22. Streilein JW. Anterior chamber associated immune deviation: the privilege of immunity in the eye. Surv Ophthalmol. 1990;35:1:67-73.
23. Streilein JW. Ocular immune privilege and the Faustian dilemma. Invest Ophthalmol Vis Sci. 1996;37:1940-1950.
24. Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol. 1990;48:191-226.
25. Wilbanks GA, Streilein JW. The differing patterns of antigen release and local retention following anterior chamber and intravenous inoculation of soluble antigen. Evidence that the eye acts as an antigen depot. Reg Immunol. 1989;2:390-398.
26. Wilbanks GA, Streilein JW. Distinctive humoral immune responses following anterior chamber and intravenous administration of soluble antigen. Evidence for active suppression of IgG2-secreting B lymphocytes. Immunology. 1990;71:566-572.
27. Giese MJ, Mondino BJ, Glasgow BJ, et al. Complement system and host defense against Staphylococcal endophthalmitis. Invest Ophthalmol Vis Sci. 1994;35:1026-1032.